Trials / Conditions / Diffuse Large B Cell Lymphoma Refractory

Diffuse Large B Cell Lymphoma Refractory

19 registered clinical trials studyying Diffuse Large B Cell Lymphoma Refractory — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed NCT07387848	American University of Beirut Medical Center	Phase 2
Not Yet Recruiting	Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848	Abramson Cancer Center at Penn Medicine	Phase 1
Recruiting	A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558	Lyell Immunopharma, Inc.	Phase 3
Recruiting	A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relap NCT06703892	GenomeFrontier Therapeutics TW Co., Ltd.	Phase 1
Recruiting	A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL NCT06789159	Thomas Jefferson University	Phase 1
Recruiting	Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL NCT06570447	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse NCT06271057	The Lymphoma Academic Research Organisation	Phase 2
Recruiting	CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619	Nathan Denlinger	Phase 1
Withdrawn	R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or NCT05966233	Fondazione Italiana Linfomi - ETS	Phase 2
Unknown	Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL NCT06033820	RenJi Hospital	Phase 2
Recruiting	A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL NCT06086197	Zhejiang Cancer Hospital	Phase 2
Terminated	A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participa NCT05121103	Epizyme, Inc.	Phase 1
Completed	Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy NCT04703686	The Lymphoma Academic Research Organisation	Phase 2
Unknown	Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL NCT03795571	The First Affiliated Hospital with Nanjing Medical University	Phase 1
Completed	Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Di NCT03589469	ADC Therapeutics S.A.	Phase 2
Unknown	Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL NCT03367143	Ruijin Hospital	Phase 2
Terminated	Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell NCT02594163	Seagen Inc.	Phase 2
Completed	Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cel NCT02142049	Pharmacyclics LLC.	Phase 1 / Phase 2
Completed	Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large NCT01805557	Fondazione Italiana Linfomi - ETS	Phase 2 / Phase 3